BioNTech Plans Buyback, Dividend With Covid Vaccine Windfall (3)

BioNTech SE plans to return some of the windfall from its best-selling Covid-19 vaccine to shareholders with a special dividend and a share buyback of as much as $1.5 billion.

The German company’s American depositary receipts surged as much as 7.1% in U.S. trading. Before the announcement, BioNTech’s ADRs had lost more than 60% of their value since hitting a peak in August last year.

The pandemic transformed BioNTech into one of Europe’s leading biotechs and the vaccine it developed with Pfizer Inc. into the best-selling pharmaceutical product of all time. The company is now grappling with how best to ...